JP Morgan Maintains Overweight on Scholar Rock Holding, Lowers Price Target to $18
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 03 2024
0mins
Source: Benzinga
Real-time Intelligence for Traders: Benzinga Pro offers fast and accurate stock market intelligence, helping traders stay informed and make winning trades daily.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like SRRK with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on SRRK
Wall Street analysts forecast SRRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRRK is 50.00 USD with a low forecast of 42.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 43.130
Low
42.00
Averages
50.00
High
60.00
Current: 43.130
Low
42.00
Averages
50.00
High
60.00
About SRRK
Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Scholar Rock Grants 35,200 Shares in Inducement Awards to New Hires
- Inducement Awards: Scholar Rock granted a total of 35,200 shares of common stock to two new employees, comprising 20,400 shares in stock options and 14,800 shares in restricted stock units, aimed at attracting top talent to the company.
- Option Exercise Price: The granted stock options have an exercise price of $43.56 per share, matching the closing price of Scholar Rock's common stock on January 12, 2026, ensuring that new hires' interests are closely aligned with the company's stock performance.
- Vesting Schedule: 25% of the stock options will vest on the first anniversary of each employee's start date, with the remaining 75% vesting in 12 equal quarterly installments, while the restricted stock units will vest in four equal annual installments, ensuring ongoing employee commitment to the company.
- Plan Background: This grant is made under the company's inducement equity plan adopted on June 16, 2022, designed to attract individuals who were not previously employed by Scholar Rock, in compliance with Nasdaq listing rules.
Continue Reading
Insider Buying Update for Wednesday, December 17: SRRK, ADGM
Insider Purchase at Scholar Rock: Srinivas Akkaraju bought 29,599 shares of Scholar Rock Holding (SRRK) for $1.18M at $39.92 each, seeing a 13.5% gain during the trading session.
Previous Investment by Akkaraju: Prior to this purchase, Akkaraju had acquired $18.81M worth of shares at $37.58 each within the last year.
Adagio Medical Holdings CEO Purchase: Todd Usen, CEO of Adagio Medical Holdings, purchased 207,315 shares for $225,973 at $1.09 each, while the stock was down about 2.5% on the day.
Market Performance: Scholar Rock Holding's stock was up approximately 0.4% on Wednesday, with SRRK reaching a high of $45.32 during trading.
Continue Reading